Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 11, 2006

Symphogen and Meiji Seika Kaisha Partner on Recombinant pAB Product

  • Symphogen and Meiji Seika Kaisha entered into a research, development, and commercialization related to a bacterial pathogen that the companies have not disclosed. Symphogen will use its antibody discovery technology, Symplex™, to develop a fully human recombinant polyclonal antibody (pAb) product candidate that targets this pathogen.

    Meiji has agreed to fund the development costs associated with the program. Symphogen will receive an initial technology access fee from Meiji and is eligible to receive development milestone payments and royalties on worldwide net sales from any successfully developed products. Symphogen has retained certain co-development option rights in the U.S. and E.U.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »